Tumor Burden Index as a Prognostic Tool for Cutaneous T-Cell Lymphoma

Schmid, M. Hess; Bird, Patricia; Dummer, Reinhard; Kempf, Werner; Burg, Günter

doi:10.1001/archderm.135.10.1204

Cited by 41 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others [13][14][15][16] have described a tumor burden index (TBI) for MF that is based on a retrospectively derived equation, the most recent being: TBI = 1 + (patches ϫ 2) + (plaquesϫ2)+(tumorsϫ1.3), where the factor for patches equals zero if there is 30% or less TBSA patch involvement, 1 if greater than 30% TBSA, 1 if plaques or tumors are present, and 0 if absent. Based on the most recent report, 6 possible TBI scores exist (1, 2.3, 3, 4.3, 5, and 6.3).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quantifying Skin Disease Burden in Mycosis Fungoides–Type Cutaneous T-Cell Lymphomas

Stevens¹,

Ke²,

Parry³

et al. 2002

Arch Dermatol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…15 However, more recently, this group suggests the TBI to be most useful as a prognostic tool for individual patients at the time of presentation. 16 This score could then help guide treatment strategies based on their survival expectancy. The authors further point out that the TBI cannot be used to monitor changes in a patient's disease.…”

Section: Discussionmentioning

confidence: 99%

Quantifying Skin Disease Burden in Mycosis Fungoides–Type Cutaneous T-Cell Lymphomas

Stevens¹,

Ke²,

Parry³

et al. 2002

Arch Dermatol

View full text Add to dashboard Cite

“…The patients were staged clinically according to the Ann Arbor system, 16 except for cases with skin tumors, which were staged according to the TNM staging of cutaneous TCL. 23 Survival was analyzed as a function of time from histologic diagnosis to the last date of follow-up in December 2002, using Kaplan-Meier product limit method. The upper aerodigestive tract included nasal, paranasal sinuses, nasopharynx, pharynx, oral cavity, hypopharynx and tonsillar regions.…”

Section: Clinical Findingsmentioning

confidence: 99%

Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore

et al. 2004

View full text Add to dashboard Cite

We studied the clinicopathologic features of 42 cases of nasal-type extranodal natural killer (NK)/T-cell lymphoma in Singapore and compared our findings with other series reported in the Asian and Western populations. A panel of immunohistochemical stains, which included CD2, CD3, CD4, CD8, CD56, T-cell intracellular Antigen-1 and granzyme B, and in situ hybridization for Epstein-Barr virus encoded RNA (EBER) were performed. Polymerase chain reaction for T-cell receptor-gamma gene rearrangement using both gel and capillary electrophoresis were evaluated to determine the proportion of tumors which are of true T-cell lineage. We also studied the functional status of the overexpressed p53 protein in these lymphomas by correlating p53 expression with its downstream target protein, p21. In all, 31 out of 42 cases presented in the upper aerodigestive tract. The other sites of involvement included gastrointestinal tract, skin, soft tissue, testis, liver, spleen, bone marrow and brain. The tumors displayed characteristic morphologic features. In situ hybridization for EBER was detected in 41 out of 42 cases (97.6%). The only significant adverse prognostic factor identified was an International Prognostic Index of two or more. A significantly higher proportion of the tumors (27%), compared to previous studies, demonstrated monoclonal T-cell receptor-gamma gene rearrangement. There was, however, no difference in survival or clinicopathologic features between the true NK-cell tumors and their T-cell counterparts. Overexpression of p53 was present in 40% of the cases, but no significant difference in survival rate was detected in patients with p53 overexpression and there was no association between p53 overexpression with large cell morphology, and advanced stage of disease. These findings suggest that molecular aberrations other than those of the p53 pathway may be operative in the pathogenesis of this malignancy.

show abstract

“…[1][2][3][4][5][6][7][8][9][10][11][12][13] These factors include basic demographic factors, the extent and type of skin involvement, the presence of extracutaneous disease, lymphadenopathy, and peripheral blood involvement. [14][15][16][17] Other potential prognostic factors that have been studied include large-cell transformation, 18 philia, levels of serum interleukin 2 receptor 20 and tumorinfiltrating T cells, 21 expressions of cytokines and adhesion molecules, histological variables, 22 tumor burden index, 23 thickness of cutaneous infiltrate, erythrocyte sedimentation rate, B symptoms, and clinical response to therapy. Despite these reports, long-term follow-up studies of large groups of patients with MF and SS are limited.…”

mentioning

confidence: 99%